<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recovery from <z:hpo ids='HP_0001297'>stroke</z:hpo> is limited, in part, by an inhibitory environment in the postischemic brain, but factors preventing successful remodeling are not well known </plain></SENT>
<SENT sid="1" pm="."><plain>Using cultured cortical neurons from mice, brain endothelial cells, and a mouse model of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, we show that signaling from the axon guidance molecule Sema3A via eicosanoid second messengers can contribute to this inhibitory environment </plain></SENT>
<SENT sid="2" pm="."><plain>Either 90 nM recombinant Sema3A, or the 12/15-lipoxygenase (12/15-LOX) metabolites <z:chebi fb="0" ids="19138">12-HETE</z:chebi> and 12-<z:chebi fb="0" ids="24644">HPETE</z:chebi> at 300 nM, block axon extension in neurons compared to solvent controls, and decrease tube formation in endothelial cells </plain></SENT>
<SENT sid="3" pm="."><plain>The Sema3A effect is reversed by inhibiting 12/15-LOX, and neurons derived from 12/15-LOX-knockout mice are insensitive to Sema3A </plain></SENT>
<SENT sid="4" pm="."><plain>Following middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> to induce <z:hpo ids='HP_0001297'>stroke</z:hpo> in mice, immunohistochemistry shows both Sema3A and 12/15-LOX are increased in the cortex up to 2 wk </plain></SENT>
<SENT sid="5" pm="."><plain>To determine whether a Sema3A-dependent damage pathway is activated following <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, we injected recombinant Sema3A into the striatum </plain></SENT>
<SENT sid="6" pm="."><plain>Sema3A alone did not cause injury in <z:mpath ids='MPATH_458'>normal</z:mpath> brains </plain></SENT>
<SENT sid="7" pm="."><plain>But when injected into postischemic brains, Sema3A increased cortical damage by 79%, and again, this effect was reversed by 12/15-LOX inhibition </plain></SENT>
<SENT sid="8" pm="."><plain>Our findings suggest that blocking the semaphorin pathway should be investigated as a therapeutic strategy to improve <z:hpo ids='HP_0001297'>stroke</z:hpo> recovery.-Pekcec, A., Yigitkanli, K., Jung, J </plain></SENT>
<SENT sid="9" pm="."><plain>E., Pallast, S., Xing, C., Antipenko, A., Minchenko, M., Nikolov, D </plain></SENT>
<SENT sid="10" pm="."><plain>B., Holman, T </plain></SENT>
<SENT sid="11" pm="."><plain>R., Lo, E </plain></SENT>
<SENT sid="12" pm="."><plain>H.,van Leyen, K </plain></SENT>
<SENT sid="13" pm="."><plain>Following experimental <z:hpo ids='HP_0001297'>stroke</z:hpo>, the recovering brain is vulnerable to lipoxygenase-dependent semaphorin signaling </plain></SENT>
</text></document>